NCT05077384CompletedPhase 1
An Open-Label Study of Surufatinib in Japanese Patients With Neuroendocrine Tumors
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Hutchmed
- Enrollment
- 36
- Locations
- 12
- Primary Endpoint
- Part 1: Incidence of treatment-emergent adverse events (TEAEs) graded by the Investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0).
Study Overview
Brief Summary
This is a phase 1/2, open-label, multi-centre study of surufatinib in patients with unresectable, locally advanced, or recurrent nonhematologic malignancies who do not respond or are intolerant to standard of care.
Detailed Description
The purpose of this study is to evaluate the tolerability and efficacy of surufatinib in Japanese patients.
The study will be conducted in 2 parts:
- Part 1 - evaluation of tolerability and safety of surufatinib and confirmation of the recommended clinical dose in Japanese patients with nonhematologic malignancies
- Part 2 - evaluation of antitumor activity and confirmation of tolerability of surufatinib in Japanese patients with NETs
All patients will be treated with oral surufatinib 300 mg QD in treatment cycles of 28 days starting on Cycle 1 Day 1.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically or cytologically documented disease as follows:
- •Part 1: unresectable, locally advanced or metastatic nonhematologic malignancy that is relapsed/refractory to or intolerant of established therapies known to provide clinical benefit
- •Part 2: locally advanced or metastatic, low (grade 1) or intermediate (grade 2) grade NETs that have been previously treated with at least 1 line of systemic therapy
- •Has radiologic evidence of progressive tumour within 12 months of study enrolment
- •Is willing and able to provide informed consent
- •Is ≥20 years of age
- •Has measurable lesions according to RECIST Version 1.1
- •Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Female patients of childbearing potential and male patients with partners of childbearing potential agree to use a highly effective form(s) of contraception
Exclusion Criteria
- •Women who are pregnant and lactating, or possibly pregnant.
- •Has a history of interstitial lung disease (ILD)/noninfectious pneumonitis, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- •Known active viral hepatits
- •Has an AE due to previous anti-tumour therapy that has not recovered to ≤CTCAE Grade 1, except alopecia and peripheral neurotoxicity with ≤CTCAE Grade 2 caused by platinum chemotherapy
- •Uncontrollable hypertension, defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, despite antihypertensive medication
- •Gastrointestinal disease or condition within 6 months prior to first dose
- •Has a history or presence of a serious haemorrhage (>30 mL within 3 months) or haemoptysis (>5 mL blood within 4 weeks)
- •Clinically significant cardiovascular disease.
- •Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of stable disease (SD) for 14 days or longer; patients requiring steroids within 4 weeks prior to start of study treatment will be excluded.
- •A high risk of bleeding at screening due to tumour invasion into major vessels, such as pulmonary artery, the superior vena cava, or the inferior vena cava, as determined by investigators.
- •Has arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing, or thromboembolic events (including stroke and/or transient ischaemic attack) within 12 months prior to first dosing.
Arms & Interventions
Surufatinib
Experimental
Oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1
Intervention: Surufatinib (Drug)
Outcomes
Primary Outcomes
Part 1: Incidence of treatment-emergent adverse events (TEAEs) graded by the Investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0).
Time Frame: Up to 2 years
To evaluate surufatinib-related adverse events in patients with NETs
Part 2: Objective response rate. This will be assessed on the proportion of participants with partial response or complete response as determined by the Investigator based on RECIST v1.1
Time Frame: Up to 2 years
The primary outcome of part 2 will be objective response rate in patients with NETs when treated with surufatinib
Secondary Outcomes
- Progression Free Survival (PFS) which is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator based on RECIST v1.1, or death from any cause, whichever occurs first(Up to 2 years)
- Duration of Response (DOR) which will be defined as the time from the first response to disease progression documented after treatment initiation or death, whichever occurs first. DOR will include CR, CR plus CRi, overall response (OR), and CR plus CRh.(Up to 2 years)
- Observed plasma concentrations of surufatinib which will be assessed by the Cmax, tmax, AUC, Cmin and CL/F(Up to 2 years)
Investigators
Study Sites (12)
Loading locations...
Similar Trials
Terminated
Phase 2
Open-Label Surufatinib in European Patients With NETNeuroendocrine TumoursNeuroendocrine Tumour of the LungSmall Intestinal NETNCT04579679Hutchmed78
Active, not recruiting
Phase 1
Open-label study of surufatinib in Japanese patientsJPRN-jRCT2031210310ITOIGAWA Suguru37
Completed
Phase 1
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid TumorsSolid TumorOsteosarcomaNon-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)LymphomaRhabdomyosarcomaEwing SarcomaNCT05093322Hutchmed13
Unknown
Phase 2
Surufatinib in Recurrent/Metastatic Head and Neck AdenocarcinomasHead and Neck Cancers - Salivary GlandNCT04910854Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University27
Terminated
Phase 1
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsMetastatic Solid TumorNeuroendocrine TumorsSoft Tissue SarcomaAnaplastic Thyroid CancerSmall Cell Lung CancerColorectal CancerGastric CancerNCT04579757Hutchmed87